These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 7867200

  • 1. Activated clotting time as an appropriate test to compare heparin and direct thrombin inhibitors such as hirudin or Ro 46-6240 in experimental arterial thrombosis.
    Carteaux JP, Gast A, Tschopp TB, Roux S.
    Circulation; 1995 Mar 01; 91(5):1568-74. PubMed ID: 7867200
    [Abstract] [Full Text] [Related]

  • 2. Effects of napsagatran (Ro 46-6240), a new synthetic thrombin inhibitor and of heparin in a canine model of coronary artery thrombosis: comparison with an ex vivo annular perfusion chamber model.
    Roux S, Tschopp T, Baumgartner HR.
    J Pharmacol Exp Ther; 1996 Apr 01; 277(1):71-8. PubMed ID: 8613969
    [Abstract] [Full Text] [Related]

  • 3. Sustained antithrombotic activity of hirudin after its plasma clearance: comparison with heparin.
    Agnelli G, Renga C, Weitz JI, Nenci GG, Hirsh J.
    Blood; 1992 Aug 15; 80(4):960-5. PubMed ID: 1498336
    [Abstract] [Full Text] [Related]

  • 4. A technique to investigate microvascular mural thrombus formation in arteries and veins: II. Effects of aspirin, heparin, r-hirudin, and G-4120.
    Stockmans F, Stassen JM, Vermylen J, Hoylaerts MF, Nyström A.
    Ann Plast Surg; 1997 Jan 15; 38(1):63-8. PubMed ID: 9015542
    [Abstract] [Full Text] [Related]

  • 5. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban.
    Finkle CD, St Pierre A, Leblond L, Deschenes I, DiMaio J, Winocour PD.
    Thromb Haemost; 1998 Feb 15; 79(2):431-8. PubMed ID: 9493603
    [Abstract] [Full Text] [Related]

  • 6. Comparative antithrombotic effects of heparin, recombinant hirudin and argatroban in a hamster femoral vein platelet-rich mural thrombosis model.
    Imura Y, Stassen JM, Collen D.
    J Pharmacol Exp Ther; 1992 Jun 15; 261(3):895-8. PubMed ID: 1602394
    [Abstract] [Full Text] [Related]

  • 7. Experimental carotid thrombosis in the guinea pig.
    Roux S, Carteaux JP, Hess P, Falivene L, Clozel JP.
    Thromb Haemost; 1994 Feb 15; 71(2):252-6. PubMed ID: 8191408
    [Abstract] [Full Text] [Related]

  • 8. Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function.
    Himber J, Kirchhofer D, Riederer M, Tschopp TB, Steiner B, Roux SP.
    Thromb Haemost; 1997 Sep 15; 78(3):1142-9. PubMed ID: 9308768
    [Abstract] [Full Text] [Related]

  • 9. Comparison of the antithrombotic effect of the new recombinant hirudin HBW 023 and heparin in small arteries and veins.
    Zhang B, Wieslander JB.
    Microsurgery; 1996 Sep 15; 17(2):89-96. PubMed ID: 8914063
    [Abstract] [Full Text] [Related]

  • 10. Prevention of early reocclusion after thrombolysis of copper coil-induced thrombi in the canine carotid artery: comparison of PEG-hirudin and unfractionated heparin.
    Rübsamen K, Hornberger W.
    Thromb Haemost; 1996 Jul 15; 76(1):105-10. PubMed ID: 8819261
    [Abstract] [Full Text] [Related]

  • 11. Differential inhibition of thrombin activity and thrombin generation by a synthetic direct thrombin inhibitor (napsagatran, Ro 46-6240) and unfractionated heparin in patients with deep vein thrombosis. ADVENT Investigators.
    Bounameaux H, Ehringer H, Gast A, Hulting J, Rasche H, Rapold HJ, Reber G, Tschopp TB.
    Thromb Haemost; 1999 Apr 15; 81(4):498-501. PubMed ID: 10235427
    [Abstract] [Full Text] [Related]

  • 12. Comparison of thrombin active site and exosite inhibitors and heparin in experimental models of arterial and venous thrombosis and bleeding.
    Schumacher WA, Steinbacher TE, Heran CL, Seiler SM, Michel IM, Ogletree ML.
    J Pharmacol Exp Ther; 1993 Dec 15; 267(3):1237-42. PubMed ID: 8263785
    [Abstract] [Full Text] [Related]

  • 13. An exploratory trial of two dosages of a novel synthetic thrombin inhibitor (napsagatran, Ro 46-6240) compared with unfractionated heparin for treatment of proximal deep-vein thrombosis -- results of the European multicenter ADVENT trial.
    Bounameaux H, Ehringer H, Hulting J, Rasche H, Rapold HJ, Zultak M.
    Thromb Haemost; 1997 Sep 15; 78(3):997-1002. PubMed ID: 9308743
    [Abstract] [Full Text] [Related]

  • 14. Laboratory assays for the evaluation of recombinant hirudin.
    Walenga JM, Hoppensteadt D, Koza M, Wallock M, Pifarre R, Fareed J.
    Haemostasis; 1991 Sep 15; 21 Suppl 1():49-63. PubMed ID: 1894197
    [Abstract] [Full Text] [Related]

  • 15. Experimental thrombosis on a collagen coated arterioarterial shunt in rats: a pharmacological model to study antithrombotic agents inhibiting thrombin formation and platelet deposition.
    Freund M, Mantz F, Nicolini P, Gachet C, Mulvihill J, Meyer L, Beretz A, Cazenave JP.
    Thromb Haemost; 1993 May 03; 69(5):515-21. PubMed ID: 8322274
    [Abstract] [Full Text] [Related]

  • 16. The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits.
    Agnelli G, Pascucci C, Cosmi B, Nenci GG.
    Thromb Haemost; 1990 Apr 12; 63(2):204-7. PubMed ID: 2363121
    [Abstract] [Full Text] [Related]

  • 17. Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin.
    Mruk JS, Zoldhelyi P, Webster MW, Heras M, Grill DE, Holmes DR, Fuster V, Chesebro JH.
    Circulation; 1996 Feb 15; 93(4):792-9. PubMed ID: 8641009
    [Abstract] [Full Text] [Related]

  • 18. Antithrombotic activity of argatroban in experimental thrombosis in the rabbit.
    Berry CN, Girard D, Girardot C, Lochot S, Lunven C, Visconte C.
    Semin Thromb Hemost; 1996 Feb 15; 22(3):233-41. PubMed ID: 8836007
    [Abstract] [Full Text] [Related]

  • 19. Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease.
    Cannon CP, Maraganore JM, Loscalzo J, McAllister A, Eddings K, George D, Selwyn AP, Adelman B, Fox I, Braunwald E.
    Am J Cardiol; 1993 Apr 01; 71(10):778-82. PubMed ID: 8456753
    [Abstract] [Full Text] [Related]

  • 20. Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time.
    Berry CN, Girard D, Lochot S, Lecoffre C.
    Br J Pharmacol; 1994 Dec 01; 113(4):1209-14. PubMed ID: 7889274
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.